
|Articles|February 1, 2003
Established Paradigm
Paris - Combination immunotherapy for psoriasis is coming into the clinic. Experience is showing it can be a valuable strategy for increasing efficacy while minimizing toxicity, both acutely and potentially over the longer term, Christopher E.M. Griffiths, M.D., said at the World Congress of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5


















